New hope for kids with deadly brain and nerve cancers: custom immune attack
NCT ID NCT04837547
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 35 times
Summary
This early-stage trial tests a personalized treatment for children with recurrent neuroblastoma or newly diagnosed DIPG, two aggressive cancers. The approach combines targeted drugs with a custom-made immune therapy using the child's own cells, including dendritic cells, immune cells, and stem cells. The main goal is to check safety and find the best dose, not yet to prove a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Children's Hospital
Charlotte, North Carolina, 28204, United States
-
Penn State Milton S. Hershey Medical Center and Children's Hospital
Hershey, Pennsylvania, 17033, United States
-
University of Florida
Gainesville, Florida, 32611, United States
Conditions
Explore the condition pages connected to this study.